Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Completed

Conditions: Intrahepatic Cholangiocarcinoma
Combined Hepatocellular and Cholangiocarcinoma

Interventions: Drug: derazantinib

Registration Number: NCT03230318

Lead Sponsor: Basilea Pharmaceutica

Brief Summary: This Phase II, open-label, single-arm study evaluated the anti-cancer activity of derazantinib in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) who received at least one prior regimen of systemic therapy. Patients received an oral once-daily total dose of 300 mg derazantinib capsules.

Detailed Description: This was a multi-center, open-label, single arm study which evaluated the anti-cancer activity of derazantinib in adult patients with inoperable or advanced iCCA in the following study population:

Patients with inoperable or advanced iCCA and with fibroblast growth factor receptor 2 (FGFR2) fusions (Substudy 1) or FGFR2 mutations/amplifications (Substudy 2), treated with at least one prior regimen of systemic therapy.

Derazantinib was supplied as 100 mg capsules. A dose of 300 mg once-daily (three capsules of 100 mg each) of derazantinib was administered orally to patients, 1 hour before, or 2 hours after, a meal.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 148

Inclusion Criteria

Signed written informed consent granted prior to initiation of any study-specific procedures
18 years of age or older
Histologically or cytologically confirmed locally advanced, inoperable, or metastatic iCCA or mixed histology tumors
Substudy 1:

FGFR2 fusion status based on the following assessments:

a) If central laboratory was designated by Sponsor: Positive FISH test; and/or b) If non-central laboratory: i) Positive FISH or NGS test: patients were potentially enrolled and started dosing, but central confirmation was required* ii) Negative FISH or NGS test: tissue was submitted to the central laboratory designated by the Sponsor, and patients were only enrolled in case the central test was positive

*By used standard protocols and approved by local IRB/EC, by CLIA or other similar agency.

Substudy 2:

FGFR2 mutation/amplification status based on local NGS testing performed or commissioned by the respective study site.
Received at least one regimen of prior systemic therapy and then experienced documented radiographic progression
Measurable disease by RECIST version 1.1 criteria
ECOG performance status ≤ 1
Adequate organ functions as indicated by the following laboratory values (based on screening visit values from the central laboratory).
- Hematological
  - Hemoglobin (Hgb) ≥ 9.0 g/dL
  - Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
  - Platelet count ≥ 75 x 109/L
  - International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects who received anticoagulant therapy such as Coumadin or heparin
- Hepatic
  - Total bilirubin ≤ 2 x ULN
  - AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)
  - Albumin ≥ 2.8 g/dL
- Renal
  - Serum creatinine ≤ 1.5 x ULN
  - Creatinine clearance of ≥ 30 mL/min as estimated by the Cockcroft-Gault equation
Female and male patients of child-producing potential must had agreed to avoid becoming pregnant or impregnating a partner, respectively, used double-barrier contraceptive measures, oral contraception, or had to avoid of intercourse, during the study, and until at least 120 for 90 days after the last dose of derazantinib.

Male or female patients of child-producing potential must had agreed to comply with one of the following until at least 120 days after the last dose of derazantinib:

Abstinence from heterosexual activity
Using (or having their partner use) an acceptable method of contraception during heterosexual activity.

Key

Exclusion Criteria

Receipt of treatment before the first dose of study drug (Cycle 1 Day 1) within an interval shorter than the following, as applicable:
- One chemotherapy or biological (e.g., antibody) cycle interval
- Five half-lives of any small-molecule investigational or licensed medicinal product
- Two weeks, for any investigational medicinal product with an unknown half-life
- Four weeks of curative radiotherapy
- Seven days of palliative radiotherapy
- 28 days of radiotherapy
Major surgery, locoregional therapy, or radiation therapy within four weeks of the first dose of derazantinib
Previous treatment with any FGFR inhibitor (e.g., Balversa® [erdafitinib], Pemazyre® [pemigatinib], infigratinib, rogaratinib, futibatinib, lenvatinib, ponatinib, dovitinib, nintedanib, AZD4547, LY2784455).
Patients who were unable or unwilling to swallow the complete daily dose of derazantinib capsules
Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects must had stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and/or had CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications)
Evidence of clinically significant corneal or retinal disorder which was likely to increase the risk of eye toxicity, including but not limited to bullous/band keratopathy, keratoconjunctivitis (unless keratoconjunctivitis sicca), corneal abrasion, inflammation/ulceration, confirmed by ophthalmologic examination.
Uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects had to be treated and disorders/complications should had been resolved within 2 weeks prior to the first dose of derazantinib)
History of significant cardiac disorders:
- Myocardial infarction (MI) or congestive heart failure defined as Class II to IV per the New York Heart Association (NYHA) classification within 6 months of the first dose of derazantinib (MI that occurred > 6 months prior to the first dose of derazantinib was permitted)
- QTcF >450 msec (males or females)
Serum electrolyte abnormalities defined as follows:
- Hyperphosphataemia: Serum phosphate > institutional ULN
- Hyperkalemia: > 6.0 mmol/L
- Hypokalemia: < 3.0 mmol/L
- Hypercalcemia: corrected serum calcium < 1.75 mmol/L (< 7.0 mg/dL)
- Hypocalcemia: corrected serum calcium > 3.1 mmol/L (> 12.5 mg/dL)
- Hypomagnesemia: < 0.4 mmol/L (< 0.9 mg/dL)
Significant gastrointestinal disorder(s) that could had, in the opinion of the Investigator, interfered with the absorption, metabolism, or excretion of derazantinib (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
History of additional malignancy that was progressing or required active treatment. Exceptions included basal cell carcinoma of the skin, squamous cell carcinoma of the skin that had undergone potentially curative therapy, and in situ cervical cancer.
Uncontrolled illness not related to cancer, including but not limited to:
- Psychiatric illness/substance abuse/social situation that would limit compliance with study requirements
- Known uncontrolled human immunodeficiency virus (HIV) infection
- Severe bacterial, fungal, viral and/or parasitic infections on therapeutic oral or IV medication at the time of first dose of study drug administration
Blood or albumin transfusion within 5 days of the blood draw which has been used to confirm eligibility
Pregnant or breast feeding
Known hypsersensitivity to derazantinib, or to any of the study drug excipients (starch, lactose, crospovidone, magnesium stearate)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
derazantinib	derazantinib	Oral administration

Primary Outcome Measures

Name	Time	Method
Substudy 1: Objective Response Rate (ORR)	From first dose and up to 54 months	ORR was defined as the proportion of patients who achieved a confirmed clinical response (CR) or partial response (PR) by blinded independent central review using the internationally recognized criteria for the radiological assessment in tumor response of solid tumors (RECIST) Version 1.1
Substudy 2: Progression Free Survival at 3 Months (PFS 3)	From first dose and up to 3 months	PFS3 was defined as the proportion of patients who have progression-free survival at 3 months from the first date of receiving study drug as assessed by survival status and blinded independent central review as per RECIST 1.1.

Secondary Outcome Measures

Name	Time	Method
PFS	From first dose and up to 54 months	PFS was calculated from the first date of receiving study drug until radiographic disease progression by blinded independent central review or death.
Duration of Response (DoR)	From first dose and up to 54 months	DoR was calculated from the first date of documented tumor response to disease progression by blinded independent central review per RECIST version 1.1 DoR was derived only for patients who have the best overall response of CR or PR
Overall Survival (OS)	From first dose and up to 54 months	OS was calculated from the first date of receiving study drug until death
Substudy 2: Objective Response Rate	From first dose and up to 54 months	ORR was defined as the proportion of patients who achieved a confirmed clinical response (CR) or partial response (PR) by blinded independent central review using the internationally recognized criteria for the radiological assessment in tumor response of solid tumors (RECIST) Version 1.1
Number of Patients With Grade 3-5 Treatment-emergent Adverse Events (TEAEs)	TEAEs were defined as all events occurring after drug treatment began and up to 30 days after last study drug administration	Number of patients experiencing TEAE of Grade 3 to 5 according to Common Terminology Criteria for Adverse Events (CTCAE)

Trial Locations

Locations (39): Antwerp University Hospital
🇧🇪
Edegem, Belgium
Vanderbilt-Ingram Cancer Center
🇺🇸
Nashville, Tennessee, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
The University of Texas Southwestern Medical Center
🇺🇸
Dallas, Texas, United States
Tom Baker Cancer Centre
🇨🇦
Calgary, Alberta, Canada
Hôpital Erasme
🇧🇪
Brussels, Belgium
Cliniques Universitaires Saint-Luc
🇧🇪
Brussels, Belgium
Sant'Orsola-Malpighi Hospital, University of Bologna
🇮🇹
Bologna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹
Milan, Italy
Winship Cancer Institute of Emory University
🇺🇸
Atlanta, Georgia, United States
Moffitt Cancer Center
🇺🇸
Tampa, Florida, United States
Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers
🇺🇸
New York, New York, United States
Abramson Cancer Center of the University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States
University of Washington Medical Center
🇺🇸
Seattle, Washington, United States
Princess Margaret Cancer Centre
🇨🇦
Toronto, Ontario, Canada
CHU Grenoble Alpes
🇫🇷
La Tronche, France
Universitätsklinikum Frankfurt
🇩🇪
Frankfurt am Main, Germany
Gustave Roussy
🇫🇷
Villejuif, France
Universitätsklinikum des Saarlandes
🇩🇪
Homburg, Germany
Medizinische Hochschule Hannover (MHH)
🇩🇪
Hannover, Germany
Universitätsklinikum Hamburg-Eppendorf (UKE)
🇩🇪
Hamburg, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
🇩🇪
Mainz, Germany
St. James's Hospital
🇮🇪
Dublin, Ireland
Ospedale San Gerardo
🇮🇹
Monza, Italy
Istituto Oncologico Veneto - IRCCS
🇮🇹
Padova, Italy
Azienda Ospedaliero-Universitaria Pisana
🇮🇹
Pisa, Italy
Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS
🇮🇹
Rozzano, Italy
Seoul National University Hospital
🇰🇷
Seoul, Korea, Republic of
Vall d'Hebrón University Hospital
🇪🇸
Barcelona, Spain
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷
Seoul, Korea, Republic of
Catalan Institute of Oncology
🇪🇸
Barcelona, Spain
Hospital Universitario 12 de Octubre
🇪🇸
Madrid, Spain
Universitätsspital Basel
🇨🇭
Basel, Switzerland
University College London Hospitals NHS Foundation Trust
🇬🇧
Euston, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧
Glasgow, United Kingdom
The Royal Marsden
🇬🇧
Sutton, United Kingdom
Samsung Medical Center
🇰🇷
Seoul, Korea, Republic of
Hospital General Universitario Gregorio Marañón
🇪🇸
Madrid, Spain
University of Texas MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States